| Q38056436 | Anti-infective properties of bacteriocins: an update |
| Q38701785 | Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries. |
| Q33804744 | Assessment of anti-plasmodial activity of non-hemolytic, non-immunogenic, non-toxic antimicrobial peptides (AMPs LR14) produced by Lactobacillus plantarum LR/14. |
| Q35778159 | Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. |
| Q34061875 | Bacteriocin production: a probiotic trait? |
| Q38069873 | Bacteriocins - a viable alternative to antibiotics? |
| Q37159542 | Bacteriocins - exploring alternatives to antibiotics in mastitis treatment |
| Q49564644 | Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology |
| Q26774123 | Bioengineering Lantibiotics for Therapeutic Success |
| Q87107449 | Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria |
| Q39751193 | Development of Class IIa Bacteriocins as Therapeutic Agents |
| Q57052048 | Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection. |
| Q37333234 | Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. |
| Q38750390 | Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics |
| Q38049200 | Modern approaches in probiotics research to control foodborne pathogens. |
| Q41676366 | Modulation of the gut microbiota by prebiotic fibres and bacteriocins |
| Q38137067 | Mutacins of Streptococcus mutans |
| Q38009935 | Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. |
| Q26997072 | New horizons for host defense peptides and lantibiotics |
| Q41916247 | Post-translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering |
| Q36364060 | Preparation of Specific Polyclonal Antibody Against the Recombinant Mutacin Produced by sfGFP Fusion Protein Technology |
| Q33866461 | Production, purification, sequencing and activity spectra of mutacins D-123.1 and F-59.1. |
| Q39383695 | Rethinking the composition of a rational antibiotic arsenal for the 21st century |
| Q37590315 | Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics |
| Q48053096 | Synergistic effect between two bacteriocin-like inhibitory substances produced by Lactobacilli Strains with inhibitory activity for Streptococcus agalactiae |
| Q35691679 | The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model. |
| Q36151378 | The Potential of Class II Bacteriocins to Modify Gut Microbiota to Improve Host Health |
| Q37160785 | The dual role of bacteriocins as anti- and probiotics |
| Q37291766 | Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics |